CiteScore of Hepatoma Research Increases to 2.5 in 2022
On June 8, 2023, Elsevier released the latest CiteScores. We are so pleased to report that our journal Hepatoma Research achieved a remarkable CiteScore of 2.5 in 2022, a significant improvement from 0.6 in 2021. Moreover, the journal has risen by 41 places among the 366 global Oncology journals. Scopus began providing CiteScores 12 years ago. The CiteScore™ journal evaluation metrics are recognized by the publishing community as relatively independent of publishers. The CiteScores is one of the most influential serial journal evaluation indicators in Scopus, used to evaluate the impact of more than 28,100 peer-reviewed journals, book series, conference papers and trade publications in the Scopus database.
This progress underscores the journal’s commitment to publishing high-quality research and its growing recognition among international researchers in the field of liver cancer.
Highly cited articles for recommendation:
1. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease
2. Epidemiology and aetiology of hepatocellular carcinoma in Sub-Saharan Africa
3. Systematic review of existing guidelines for NAFLD assessment
4. Hepatocellular carcinoma surveillance: current practice and future directions
5. Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma
6. Role of locoregional therapies in the management of patients with hepatocellular carcinoma
The Editorial Office of Hepatoma Research sincerely appreciates the dedicated support of Editorial Board Members, authors, reviewers, and readers. The journal will continue to drive advancements in liver cancer and its related diseases, fostering collaboration with prominent international scientists to further the understanding and treatment of liver cancer.
Respectfully submitted by the Editorial Office of Hepatoma Research
